Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab govitecan-hziy + bevacizumab
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Sacituzumab govitecan-hziy + bevacizumab is a combination of two anticancer agents used in investigational settings, particularly for patients with advanced or metastatic cancers such as non-squamous non-small cell lung cancer (NSCLC) with brain metastases. Sacituzumab govitecan-hziy is an antibody-drug conjugate that targets the Trophoblast cell surface antigen 2 (Trop‑2) protein on cancer cells, delivering the cytotoxic topoisomerase I inhibitor SN-38 directly into tumor cells to induce DNA damage and cell death. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis and reducing blood supply to tumors. This combination aims to leverage both targeted cytotoxicity and antiangiogenic effects for enhanced antitumor activity[1][2][3][4][5][6][7].
- Brand names
- TrodelvyAvastinZirabev
- Other names
- sacituzumab govitecanSG plus bevacizumab
02
Targets
TOP1 (DNA Topoisomerase I)VEGFA (Vascular endothelial growth factor A)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on sacituzumab govitecan-hziy + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab govitecan-hziy + bevacizumab.